Dupilumab Efficacy in Children with Palmoplantar Eczema

Background. Atopic dermatitis (AD) is a chronic inflammatory skin disease with such clinical manifestations as eczematous lesions and itching. One of its clinical forms is palmoplantar eczema. It is urgent and unresolved issue in pediatric dermatology as this disease significantly affect the patients’ quality of life due to involvement of functionally significant areas, symptoms severity, difficult induction of remission. Clinical case description. This article presents case series of patients with AD involving palms and soles who have shown positive results to the treatment with genetically engineered biologic drug — dupilumab. Conclusion. Palmoplantar eczema, as one of the forms of AD, hardly responds to topical therapy in clinical practice of dermatologist. Moreover, systemic treatment is not only limited in pediatrics, but also is not effective enough. Prescription of the genetically engineered biologic drug, dupilumab, seems to be one of the effective methods for management of this disease in these patients.

1. Ahmed A, Shah R, Papadopoulos L, Bewley A. An ethnographic study into the psychological impact and adaptive mechanisms of living with hand eczema. Clin Exp Dermatol. 2015;40(5):495–501. doi: https://doi.org/10.1111/ced.12619

2. Cazzaniga S, Ballmer-Weber BK, Gräni N, et al. Medical, psychological and socio-economic implications of chronic hand eczema: a cross-sectional study. J Eur Acad Dermatol Venereol. 2016;30(4):628–637. doi: https://doi.org/10.1111/jdv.13479

3. Armstrong A, Hahn-Pedersen J, Bartlett C, et al. Economic Burden of Chronic Hand Eczema: A Review. Am J Clin Dermatol. 2022;23(3): 287–300. doi: https://doi.org/10.1007/s40257-021-00669-6

4. Lerbaek A, Kyvik KO, Mortensen J, et al. Heritability of hand eczema is not explained by comorbidity with atopic dermatitis. J Invest Dermatol. 2007;127(7):1632–1640. doi: https://doi.org/10.1038/sj.jid.5700750

5. Agner T, Elsner P. Hand eczema: epidemiology, prognosis and prevention. J Eur Acad Dermatol Venereol. 2020;34(Suppl 1):4–12. doi: https://doi.org/10.1111/jdv.16061

6. Lerbaek A, Bisgaard H, Agner T, et al. Filaggrin null alleles are not associated with hand eczema or contact allergy. Br J Dermatol. 2007;157(6):1199–1204. doi: https://doi.org/10.1111/j.1365-2133.2007.08252.x

7. Visser MJ, Verberk MM, Campbell LE, et al. Filaggrin loss-offunction mutations and atopic dermatitis as risk factors for hand eczema in apprentice nurses: part II of a prospective cohort study. Contact Dermatitis. 2014;70(3):139–150. doi: https://doi.org/10.1111/cod.12139

8. Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1–e22. doi: https://doi.org/10.1111/ddg.12510_1

9. Caroe TK, Ebbehoj N, Agner T. A survey of exposures related to recognized occupational contact dermatitis in Denmark in 2010. Contact Dermatitis. 2014;70(1):56–62. doi: https://doi.org/10.1111/cod.12134

10. Blaabjerg MS, Andersen KE, Bindslev-Jensen C, Mortz CG. Decrease in the rate of sensitization and clinical allergy to natural rubber latex. Contact Dermatitis. 2015;73(1):21–28. doi: https://doi.org/10.1111/cod.12386

11. Hersle K, Mobacken H. Hyperkeratotic dermatitis of the palms. Br J Dermatol. 1982;107(2):195–201. doi: https://doi.org/10.1111/j.1365-2133.1982.tb00338.x

12. Johansen JD, Hald M, Andersen BL, et al. Classification of hand eczema: clinical and aetiological types. Based on the guideline of the Danish Contact Dermatitis Group. Contact Dermatitis. 2011;65(1):13–21. doi: https://doi.org/10.1111/j.1600-0536. 2011.01911.x

13. Agner T, Aalto-Korte K, Andersen KE, et al. Factors associated with combined hand and foot eczema. J Eur Acad Dermatol Venereol. 2017;31(5):828–832. doi: https://doi.org/10.1111/jdv.14016

14. Bryld LE, Agner T, Menne T. Relation between vesicular eruptions on the hands and tinea pedis, atopic dermatitis and nickel allergy. Acta Derm Venereol. 2003;83(3):186–188. doi: https://doi.org/10.1080/00015550310007184

15. Schuttelaar ML, Coenraads PJ, Huizinga J, et al. Increase in vesicular hand eczema after house dust mite inhalation provocation: a double-blind, placebo-controlled, cross-over study. Contact Dermatitis. 2013;68(2):76–85. doi: https://doi.org/10.1111/j.1600-0536.2012.02172.x

16. Luchsinger I, Vogler T, Schwieger-Briel A, et al. Safe and effective use of alitretinoin in children with recalcitrant hand eczema and other dermatoses — a retrospective analysis. J Eur Acad Dermatol Venereol. 2020;34(5):1037–1042. doi: https://doi.org/10.1111/jdv.16088

17. Ruzicka T, Lynde CW, Jemec GB, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158(4):808–817. doi: https://doi.org/10.1111/j.1365-2133.2008.08487.x

18. Garritsen FM, van der Schaft J, van den Reek JM, et al. Risk of Non-melanoma Skin Cancer in Patients with Atopic Dermatitis Treated with Oral Immunosuppressive Drugs. Acta Derm Venereol. 2017; 97(6):724–730. doi: https://doi.org/10.2340/00015555-2637

19. Halling AS, Zachariae C, Thyssen JP. Severe treatment-resistant acute and recurrent vesicular chronic hand eczema successfully treated with dupilumab. Contact Dermatitis. 2020;83(1):37–38. doi: https://doi.org/10.1111/cod.13501

20. Loman L, Diercks GFH, Schuttelaar MLA. Three cases of nonatopic hyperkeratotic hand eczema treated with dupilumab. Contact Dermatitis. 2021;84(2):124–127. doi: https://doi.org/10.1111/cod.13693

21. Oosterhaven JAF, Voorberg AN, Romeijn GLE, et al. Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study. J Dermatol. 2019;46(8):680–685. doi: https://doi.org/10.1111/1346-8138.14982

22. Voorberg AN, Romeijn GLE, de Bruin-Weller MS, Schuttelaar MLA. The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay Registry. Contact Dermatitis. 2022;87(2):185–191. doi: https://doi.org/10.1111/cod.14104

23. Lee GR, Maarouf M, Hendricks AK, et al. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3):e12840. doi: https://doi.org/10.1111/dth.12840

24. Molin S, Merl J, Dietrich KA, et al. The hand eczema proteome: imbalance of epidermal barrier proteins. Br J Dermatol. 2015;172(4):994–1001. doi: https://doi.org/10.1111/bjd.13418

25. Guttman-Yassky E, Dhingra N, Leung DYM. New era of biologic therapeutics in atopic dermatitis. Expert Opin Biol Ther. 2013;13(4):549–561. doi: https://doi.org/10.1517/14712598.2013.758708

26. Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50. doi: https://doi.org/10.1038/nrd4624